SMi's 9th Annual Conference Pre-Filled Syringes East Coast

SMi Group25 - 26 April 2022, Boston, MA, USA.
The global pre-filled syringes market was valued at $1139.6 million in 2020 and with the rapid growth of the industry, is expected to grow at a CAGR of 8.95% up to 2027. With that in mind, the 9th annual Pre-Filled Syringes East Coast conference will bring together leading industry experts representing big pharma and device developers to discuss the key drivers accelerating the expansion of the industry.

The past year has seen significant developments in the injectables landscape with the rapid introduction and development of vaccines in response to the pandemic, updates in regulations including the EU MDR and FDA guidance on bridging studies, and increasing industry acceptance of connectivity to aid the user experience. As part of SMi’s leading injectable series, the 2022 conference will provide an exclusive insight into the latest developing technologies for device design, advances in parenteral device platforms and development, insights into growing integration of digital health and deep dives into recent case studies on novel delivery systems.

This two-day agenda offers you peer-to-peer networking with Global Product Managers, Senior PFS Engineers, Device Testing Managers, Heads of Late-Stage PFS Development and many more.

Visit the website at www.pfsamericas.com

Chair for 2022

  • Gretchen Vandal, Sr. Director, Head of Global Regulatory Affairs - Devices and Combination Products, Takeda

Guest FDA Speaker

  • John Barr Weiner, Associate Director for Policy and Product Classification Office, Office of Combination

Products FDA

Featured 2022 Speakers Include:
  • Joyce Zhao, Associate Director, Combination Product, Takeda
  • Suzette Roan, Associate VP and Head of Global Device Regulatory Affairs, Sanofi US
  • Christine lynn lanning, Distinguished Scientist, Device Area Leader, Merck
  • Heather l. Guerin, Associate Director, Regulatory Affairs - CMC, Janssen
  • Tieming Ruan, Senior Director of Device Development, Alexion Pharmaceuticals
  • John Schalago, Executive Director, Senior Global Program Director Regulatory Affairs, Novartis
  • Gretchen Piwinski, Manager, Combination Product Laboratories, Regeneron
  • Michael Song, Associate Director, Takeda
  • Deep S Bhattacharya, Senior Scientist, Drug Product Development and Design, Pfizer

Benefits of attending

  • Explore the latest developments in innovative technologies for device design accelerating the path to self-administration
  • Assess the evolving regulatory landscape for pre-filled syringes and discuss approaches to work with regulators as guidance is updated
  • Engage in panel discussions with industry leaders to navigate the accelerating digital health landscape for combination products and drug delivery systems
  • Understand the landscape of delivery for novel drug products and key considerations to overcome challenges in CCI

View the full agenda and speaker line-up online www.pfsamericas.com

Who should Attend

  • Drug-delivery developers
  • Medical Device Engineers
  • Primary Packaging material designers
  • Secondary packagers
  • Smart device developers
  • Training device developers
  • Device-safety solution providers
  • Drug developers

Early-bird rates

  • Book by 31st January and save $200
  • Book by 28th February and save $100

Registrations can be made on the event website at www.pfsamericas.com

Post Conference Workshop A: EU MDR 2017/745 Article 117 Requirements

Workshop Leader: Theresa Jeary, Technical Specialist & Scheme Manager, BSi
08.30 - 12.30

Overview of the workshop The workshop is aimed to provide an introduction to the key elements of the Medical Device Regulation that Companies affected by article 117 need to consider.

Why you should attend

  • Be able to determine if Article 117 is applicable to your products
  • Understand and be able to interpret the requirements of Article 117

Understand the impacts on your marketing authorization application or post-market variation

  • Gain an appreciation and understanding of the MDR Annex I, General Safety & Performance
Requirements
  • Understand requirements to facilitate the documentation preparation needed to obtain a NB Opinion

Post Conference Workshop B: Developing User-Centric Next Generation Combination Products

Workshop Leaders: Marty Coyne, Principal & Co-Founder, Matchstick and Chris Franzese, Principal & Clinical Leader, Matchstick
13.00 - 17.00

Overview of the workshop This interactive workshop will explore approaches for developing innovative drug delivery device combination products offering tools for optimal device development with the user in mind. Workshop leaders will provide insights into effectives strategies for concept generation, product testing and validation for the future of device design.

Why you should attend

  • Discover innovative concept generation approaches for device development
  • Understand how to utilise user feedback and experiences in early stages of development
  • Walk through unique examples assessing effective testing to ensure an optimal product
  • Engage in interactive discussions to assess opportunities for enhanced devices ensuring the patient is kept at the forefront

For further information and to register, please visit:
http://www.pfsamericas.com

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network.

Most Popular Now

Salvat Laboratories announces submission of New Dr…

Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsi...

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

New insights on antibody responses to Omicron vari…

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research quest...

Ancient viral DNA in human genome guards against i…

Viral DNA in human genomes, embedded there from ancient infections, serve as antivirals that protect human cells against certain present-day viruses, according to new res...

The origin-of-life molecule, a key to cancer resea…

RNA, the molecule that gave rise to life, has been shown to be essential for repairing human genetic material and preventing mutations that might lead to developing cance...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...